Anders Hjerpe
Overview
Explore the profile of Anders Hjerpe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hjerpe A, Demir E, Abd-Own S, Dobra K
Cancer Med
. 2022 Oct;
12(5):5334-5340.
PMID: 36259232
Background: Pleural mesothelioma (PM) is typically diagnosed late during the disease. Earlier detection can increase the chance of effective therapy. Recurrent pleural effusions are the earliest symptoms displaying an array...
2.
Norman I, Yilmaz E, Hjerpe A, Hortlund M, Elfstrom K, Dillner J
Int J Cancer
. 2022 Aug;
151(11):2012-2019.
PMID: 36029205
The effect of cervical screening on cervical adenocarcinoma has been variable, possibly because the risk associated with the precursor atypical glandular cells (AGC) is not well known. A cohort of...
3.
Javadi J, Gorgens A, Vanky H, Gupta D, Hjerpe A, El-Andaloussi S, et al.
Biomolecules
. 2021 Nov;
11(11).
PMID: 34827604
Extracellular vesicles (EVs), comprising exosomes, microvesicles, and apoptotic bodies, are released by all cells into the extracellular matrix and body fluids, where they play important roles in intercellular communication and...
4.
Hortlund M, Arroyo Muhr L, Lagheden C, Hjerpe A, Dillner J
Int J Cancer
. 2021 Aug;
149(12):2083-2090.
PMID: 34418082
The globally recommended public health policy for cervical screening is primary human papillomavirus (HPV) screening with cytology triaging of positives. To ensure optimal quality of laboratory services we have conducted...
5.
Kumar-Singh A, Parniewska M, Giotopoulou N, Javadi J, Sun W, Szatmari T, et al.
Biology (Basel)
. 2021 Jul;
10(6).
PMID: 34208075
Tumor cells undergoing epithelial-mesenchymal transition (EMT) lose cell surface adhesion molecules and gain invasive and metastatic properties. EMT is a plastic process and tumor cells may shift between different epithelial-mesenchymal...
6.
Klebe S, Nakatani Y, Dobra K, Butnor K, Roden A, Nicholson A, et al.
Pathology
. 2021 Mar;
53(4):446-453.
PMID: 33775406
Diffuse malignant mesothelioma (MM) is an incurable tumour of the serosal membranes, which is often caused by exposure to asbestos and commonly diagnosed at advanced stage. Malignant mesothelioma in situ...
7.
Keller M, Reis K, Hjerpe A, Dobra K, Aspenstrom P
Cancers (Basel)
. 2021 Feb;
13(4).
PMID: 33567673
Malignant mesothelioma (MM) is a rare but highly aggressive cancer that primarily originates from the pleura, peritoneum or pericardium. There is a well-established link between asbestos exposure and progression of...
8.
Javadi J, Heidari-Hamedani G, Schmalzl A, Szatmari T, Metintas M, Aspenstrom P, et al.
Cancers (Basel)
. 2021 Feb;
13(4).
PMID: 33562126
Malignant mesothelioma (MM) is an aggressive tumor of the serosal cavities. Angiogenesis is important for mesothelioma progression, but so far, anti-angiogenic agents have not improved patient survival. Our hypothesis is...
9.
Reis K, Arbiser J, Hjerpe A, Dobra K, Aspenstrom P
Oncotarget
. 2021 Jan;
11(50):4637-4647.
PMID: 33400741
Malignant mesotheliomas (MMs) are highly aggressive mesenchymal tumors that originate from mesothelial cells lining serosal cavities; i.e., the pleura, peritoneum, and pericardium. Classically, there is a well-established link between asbestos...
10.
Javadi J, Dobra K, Hjerpe A
Biomolecules
. 2020 Aug;
10(8).
PMID: 32731396
Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy resistant pleural malignancy that is caused by asbestos exposure. MPM is associated with poor prognosis and a short patient survival....